이포스파미드

용도

• Vaccine-related sarcomas
• Neoplasia
• Lymphomas and soft tissue sarcomas
• Lymphomas and soft tissue sarcomas

투여 방법

가능한 부작용

• Myelosuppression (neutropenia at 5-7 days, potentially delayed to 14-21 days; thrombocytopenia)
• Hemorrhagic cystitis (bladder epithelial damage)
• Nephrotoxicity (proximal and distal tubular damage, electrolyte abnormalities)
• Volume overload and pulmonary edema (secondary to required saline diuresis)
• Neurotoxicity (somnolence, confusion, coma, encephalopathy)
• Gastrointestinal effects (nausea, vomiting, anorexia)
• Hypersensitivity reactions
• Alopecia
• Abnormal liver function tests

주의사항 및 금기

• Hypersensitivity to ifosfamide
• Severely depressed bone marrow function
• Active hemorrhagic cystitis
• Because of its toxicity, ifosfamide should only be used by clinicians experienced with cytotoxic agents. Must be used in conjunction with mesna and saline diuresis to reduce the risk of hemorrhagic cystitis and nephrotoxicity. Use with extreme caution in patients with impaired renal function or preexisting cardiac disease (due to volume overload risk). Handle and dispose of as a hazardous cytotoxic drug. FDA Category D for pregnancy (teratogenic and fetotoxic).

약물 상호작용

• Benzodiazepines (diazepam, chlordiazepoxide, oxazepam): May increase concentrations of active ifosfamide and increase toxicity (demonstrated in mice; clinical significance in veterinary patients undetermined)
• Cisplatin: Ifosfamide may enhance cisplatin-induced ototoxicity and nephrotoxicity
• Myelosuppressive drugs (chloramphenicol, flucytosine, amphotericin B, colchicine, other antineoplastics): Additive myelosuppression

자주 묻는 질문